NasdaqGS:TARSPharmaceuticals
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins
Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing infected ticks.
See our latest analysis for Tarsus Pharmaceuticals.
The recent TP-05 progress and TP-03 milestone in China come as the share price sits at US$70.22, with a 7 day share price return of 4.9% but a 90 day share price return showing a 14.2% decline. The 1 year total shareholder return of...